Literature DB >> 33252618

Relationships Between Sensorimotor Inhibition and Mobility in Older Adults With and Without Parkinson's Disease.

Douglas N Martini1,2, Rosie Morris1, Tara M Madhyastha3, Thomas J Grabowski3, John Oakley4, Shu-Ching Hu4,5, Cyrus P Zabetian4,5, Karen L Edwards6, Amie Hiller1,7, Kathryn Chung1,7, Katrina Ramsey8, Jodi A Lapidus8,9, Brenna Cholerton10, Thomas J Montine10, Joseph F Quinn1,7, Fay B Horak1,7.   

Abstract

BACKGROUND: Reduced cortical sensorimotor inhibition is associated with mobility and cognitive impairments in people with Parkinson's disease (PD) and older adults (OAs). However, there is a lack of clarity regarding the relationships among sensorimotor, cognitive, and mobility impairments. The purpose of this study was to determine how cortical sensorimotor inhibition relates to impairments in mobility and cognition in people with PD and OAs.
METHOD: Cortical sensorimotor inhibition was characterized with short-latency afferent inhibition (SAI) in 81 people with PD and 69 OAs. Six inertial sensors recorded single- and dual-task gait and postural sway characteristics during a 2-minute walk and a 1-minute quiet stance. Cognition was assessed across the memory, visuospatial, executive function, attention, and language domains.
RESULTS: SAI was significantly impaired in the PD compared to the OA group. The PD group preformed significantly worse across all gait and postural sway tasks. In PD, SAI significantly correlated with single-task foot strike angle and stride length variability, sway area, and jerkiness of sway in the coronal and sagittal planes. In OAs, SAI significantly related to single-task gait speed and stride length, dual-task stride length, and immediate recall (memory domain). No relationship among mobility, cognition, and SAI was observed.
CONCLUSIONS: Impaired SAI related to slower gait in OA and to increased gait variability and postural sway in people with PD, all of which have been shown to be related to increased fall risk.
© The Author(s) 2020. Published by Oxford University Press on behalf of The Gerontological Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Cognition; Gait; Short-latency afferent inhibition; Transcranial magnetic stimulation

Year:  2021        PMID: 33252618      PMCID: PMC8240993          DOI: 10.1093/gerona/glaa300

Source DB:  PubMed          Journal:  J Gerontol A Biol Sci Med Sci        ISSN: 1079-5006            Impact factor:   6.053


  41 in total

1.  Dopamine depletion impairs gait automaticity by altering cortico-striatal and cerebellar processing in Parkinson's disease.

Authors:  Moran Gilat; Peter T Bell; Kaylena A Ehgoetz Martens; Matthew J Georgiades; Julie M Hall; Courtney C Walton; Simon J G Lewis; James M Shine
Journal:  Neuroimage       Date:  2017-03-03       Impact factor: 6.556

2.  Effects of lorazepam on short latency afferent inhibition and short latency intracortical inhibition in humans.

Authors:  V Di Lazzaro; A Oliviero; E Saturno; M Dileone; F Pilato; R Nardone; F Ranieri; G Musumeci; T Fiorilla; P Tonali
Journal:  J Physiol       Date:  2005-02-17       Impact factor: 5.182

3.  Thalamic cholinergic innervation and postural sensory integration function in Parkinson's disease.

Authors:  Martijn L T M Müller; Roger L Albin; Vikas Kotagal; Robert A Koeppe; Peter J H Scott; Kirk A Frey; Nicolaas I Bohnen
Journal:  Brain       Date:  2013-09-20       Impact factor: 13.501

4.  Cognitive associations with comprehensive gait and static balance measures in Parkinson's disease.

Authors:  Rosie Morris; Douglas N Martini; Katrijn Smulders; Valerie E Kelly; Cyrus P Zabetian; Kathleen Poston; Amie Hiller; Kathryn A Chung; Laurice Yang; Shu-Ching Hu; Karen L Edwards; Brenna Cholerton; Thomas J Grabowski; Thomas J Montine; Joseph F Quinn; Fay Horak
Journal:  Parkinsonism Relat Disord       Date:  2019-07-04       Impact factor: 4.891

Review 5.  Systematic review of levodopa dose equivalency reporting in Parkinson's disease.

Authors:  Claire L Tomlinson; Rebecca Stowe; Smitaa Patel; Caroline Rick; Richard Gray; Carl E Clarke
Journal:  Mov Disord       Date:  2010-11-15       Impact factor: 10.338

Review 6.  Neurotransmission in Parkinson's disease: beyond dopamine.

Authors:  P Barone
Journal:  Eur J Neurol       Date:  2009-12-30       Impact factor: 6.089

7.  Prevalence of gait disorders in hospitalized neurological patients.

Authors:  Henning Stolze; Stephan Klebe; Christoph Baecker; Christiane Zechlin; Lars Friege; Sabine Pohle; Günther Deuschl
Journal:  Mov Disord       Date:  2005-01       Impact factor: 10.338

8.  Effects of dopamine on postural control in parkinsonian subjects: scaling, set, and tone.

Authors:  F B Horak; J Frank; J Nutt
Journal:  J Neurophysiol       Date:  1996-06       Impact factor: 2.714

Review 9.  Cholinergic dysfunction in Parkinson's disease.

Authors:  Martijn L T M Müller; Nicolaas I Bohnen
Journal:  Curr Neurol Neurosci Rep       Date:  2013-09       Impact factor: 5.081

10.  Attentional Control of Gait and Falls: Is Cholinergic Dysfunction a Common Substrate in the Elderly and Parkinson's Disease?

Authors:  Elisa Pelosin; Carla Ogliastro; Giovanna Lagravinese; Gaia Bonassi; Anat Mirelman; Jeffrey M Hausdorff; Giovanni Abbruzzese; Laura Avanzino
Journal:  Front Aging Neurosci       Date:  2016-05-09       Impact factor: 5.750

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.